The Computational Biology Support Component (Leader, Thomas Kepler) will be organized into two teams: one team at Duke under Thomas Kepler, and the other at Los Alamos led by Bette Korber and Alan Perelson. Independently and jointly, they will work to surmount the two roadblocks: HlV-1 diversity and the inability to induce broad neutralizing antibodies (BnAbs) to HIV-1 envelope. Both sites will be involved in and collaborate on statistical analyses and immunogen design, but each will have its own primary focus. The Duke team will focus on the analysis and modeling of affinity maturation toward protective antibody phenotypes, including the inference of clonal histories back to the unmutated common ancestor and integrated analysis of structural, phenotypic, and genetic antibody data. The Los Alamos team will focus on polyvalent and mosaic immunogen design to overcome HIV diversity and assist in modeling affinity maturation and antibody repertoire. Together, the teams will statistically evaluate all results obtained from testing of the various designs as well as perform co-evolutionary analyses of BnAbs and transmitted/founder viral sequences together with the Viral Biology SRSC. Both teams will contribute to immunogen design and the development of different approaches.
Specific Aims Aim 1. Statistical analysis of HIV broadly neutralizing antibodies (BnAb) and vaccine-induced antibody and virus evolution.
Aim 2. Computational design of vaccine antigens for the induction and maturation of protective antibody responses.

Public Health Relevance

The development of a vaccine against HIV infection remains a problem of great public concern. Researchers have learned a great deal recently about how the immune system and HIV-1 interact;sophisticated new approaches to vaccine design based on these findings are being tested. These methods call for correspondingly sophisticated computational methods, to be provided by the computational biology group.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-JBS-A (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Pollara, Justin; Easterhoff, David; Fouda, Genevieve G (2017) Lessons learned from human HIV vaccine trials. Curr Opin HIV AIDS 12:216-221
Arakelyan, Anush; Fitzgerald, Wendy; King, Deborah F et al. (2017) Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions. Sci Rep 7:948
Go, Eden P; Ding, Haitao; Zhang, Shijian et al. (2017) Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. J Virol 91:
Verkoczy, Laurent; Alt, Frederick W; Tian, Ming (2017) Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies. Immunol Rev 275:89-107
Haynes, Barton F; Mascola, John R (2017) The quest for an antibody-based HIV vaccine. Immunol Rev 275:5-10
Bonsignori, Mattia; Liao, Hua-Xin; Gao, Feng et al. (2017) Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol Rev 275:145-160
Kelsoe, Garnett; Haynes, Barton F (2017) What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Breaking through Immunity's Glass Ceiling. Cold Spring Harb Perspect Biol :
Herschhorn, Alon; Sodroski, Joseph (2017) An entry-competent intermediate state of the HIV-1 envelope glycoproteins. Receptors Clin Investig 4:
Ding, Shilei; Verly, Myriam M; Princiotto, Amy et al. (2017) Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. AIDS Res Hum Retroviruses 33:428-431
Espy, Nicole; Pacheco, Beatriz; Sodroski, Joseph (2017) Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor. Virology 508:90-107

Showing the most recent 10 out of 220 publications